StoneX Group’s Adial Pharmaceuticals ADIL Stock Holding History

StoneX Group’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.7K	Buy	+19,699	New	+$39K	﹤0.01%	1259
2026 Q1	–	Sell	-778	Closed	-$4.28K	–	921
2025 Q4	$4.28K	Buy	+778	New	+$6.3K	﹤0.01%	1040
2022 Q4	–	Sell	-22	Closed	-$4.83K	–	699
2022 Q3	$4.83K	Sell	22 -2	-8%	-$902	﹤0.01%	512
2022 Q2	$20.1K	Buy	+24	New	+$21.7K	﹤0.01%	641

Other funds holding ADIL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

StoneX Group's ADIL Position: Q2 2026 in Review

StoneX Group opened a new position in Adial Pharmaceuticals (ADIL) in Q2 2026: 19,699 shares worth $35.7K. The stake represents ﹤0.01% of the portfolio and ranks #1259 among its holdings. This is a return to the name: StoneX Group previously reported a position in ADIL as recently as Q4 2025.

StoneX Group first reported a position in ADIL in Q2 2022 and has held it in 4 quarters since. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

StoneX Group held 19,699 shares of Adial Pharmaceuticals worth $35.7K as of Q2 2026.
Adial Pharmaceuticals was a new StoneX Group position in Q2 2026.
Adial Pharmaceuticals made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1259 holding.
StoneX Group first reported a position in Adial Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.